From Casetext: Smarter Legal Research

Wisconsin v. Indivior Inc. (In re Suboxone (Buprenorphine Hydrochloride & Naloxone) Antitrust Litig.)

United States District Court, E.D. Pennsylvania
Feb 2, 2022
MDL 2445 13-MD-2445 (E.D. Pa. Feb. 2, 2022)

Opinion

MDL 2445 13-MD-2445

02-02-2022

IN RE SUBOXONE BUPRENORPHINE HYDROCHLORIDE AND NALOXONE ANTITRUST LITIGATION THIS DOCUMENT RELATES TO, STATE OF WISCONSIN By Attorney General Brad D. Schimel, et al. Plaintiffs, v. INDIVIOR INC. f/k/a RECKITT BENCKISER PHARMACEUTICALS, INC., et al. Defendants.


ORDER

MITCHELL S. GOLDBERG, J.

AND NOW this 2nd day of February, 2022, upon consideration of Defendant Indivior, Inc.'s Renewed Motion to Disqualify Rochester Drug Co-Operative and Its Counsel from Representing the Direct Purchaser Class (Doc. No. 735), the Direct Purchaser Plaintiffs' Response (Doc. No. 737), the Direct Purchaser Plaintiffs' Notice of Supplemental Authority (Doc. No. 767), and Defendant Indivior, Inc.'s Response to the Notice of Supplemental Authority (Doc. No. 768), it is hereby ORDERED that the Motion is DENIED.


Summaries of

Wisconsin v. Indivior Inc. (In re Suboxone (Buprenorphine Hydrochloride & Naloxone) Antitrust Litig.)

United States District Court, E.D. Pennsylvania
Feb 2, 2022
MDL 2445 13-MD-2445 (E.D. Pa. Feb. 2, 2022)
Case details for

Wisconsin v. Indivior Inc. (In re Suboxone (Buprenorphine Hydrochloride & Naloxone) Antitrust Litig.)

Case Details

Full title:IN RE SUBOXONE BUPRENORPHINE HYDROCHLORIDE AND NALOXONE ANTITRUST…

Court:United States District Court, E.D. Pennsylvania

Date published: Feb 2, 2022

Citations

MDL 2445 13-MD-2445 (E.D. Pa. Feb. 2, 2022)